Optellum

Optellum Optellum’s vision is to radically reshape cancer care from early diagnosis to treatment.

Optellum’s vision is to radically reshape cancer care, by enabling every clinician to choose the optimal diagnostic and treatment pathway for their patient. We do that by providing expert-level decision support for personalised diagnosis and treatment, based on collective experience of thousands of doctors, pooled by applying Machine Learning to vast medical image and patient record repositories. Our first suite of products targets patient risk stratification for lung cancer – the world’s deadliest and commonest cancer – from early diagnosis through to treatment. We are a team of award-winning AI and imaging experts who met at Oxford’s world-renowned computer vision laboratory, and we have track records of bringing innovation to market (including multiple trade sales, IPO). We are backed by an Advisory Board comprising world-leading clinicians and experts in deep learning and diagnostic imaging; and Oxford's most prominent investors with track records in medtech startups.

This International Women's Day we're launching our Q&A with our investor Dr Tara Bishop of Black Opal Ventures, taking a...
08/03/2024

This International Women's Day we're launching our Q&A with our investor Dr Tara Bishop of Black Opal Ventures, taking about the collision of healthcare and technology and what inspires her to invest in companies like Optellum.

Introducing Dr Tara Bishop, Black Opal Ventures, and the Optellum Virtual Nodule Clinic. Part of our celebration of International Women's Day 2024.

Optellum's vision is to redefine early intervention of lung cancer, enabling every clinician, in every hospital, to make...
01/08/2023

Optellum's vision is to redefine early intervention of lung cancer, enabling every clinician, in every hospital, to make the right decisions and give patients the best chance to fight back.

Lung cancer is the  #1 cancer killer.This   we're launching our new video showing how Optellum can help clinicians with ...
01/08/2023

Lung cancer is the #1 cancer killer.

This we're launching our new video showing how Optellum can help clinicians with the only AI-based lung cancer clinical solution for early diagnosis.​​​​​​

An animated video (no voiceover) which explains how Optellum is addressing the problem of late stage diagnosis for lung cancer.

Are you a digital communications professional based in the UK with experience in   and  ? Are you a creative communicato...
08/06/2023

Are you a digital communications professional based in the UK with experience in and ? Are you a creative communicator who enjoys using technology to reach varied audiences of customers, partners and influencers across multiple channels? Would you like to work with a talented and dedicated team to make a difference in the fight against lung cancer?

We are looking for a part time (22.5 to 30 hours per week) Digital Communications and Marketing Officer to join our fantastic team working with Head of Communications and Marketing Rhiannon Lassiter. You will be based in our Oxford office with hybrid working arrangements.

Please visit our careers page for details and send your CV and a covering letter to hr@optellum.com explaining why you'd be a great fit for this role.

https://optellum.com/careers/

UK followers, please share with your own networks to help us find the new member of our team.

Optellum is a professional, expert, inclusive and international company with offices in the USA and in Oxford, UK.

Vanderbilt University Medical Center (VUMC) is the first hospital in Tennessee to introduce Optellum’s Virtual Nodule Cl...
04/01/2022

Vanderbilt University Medical Center (VUMC) is the first hospital in Tennessee to introduce Optellum’s Virtual Nodule Clinic. The world-leading hospital was one of the first to conduct clinical trials of the software, under the leadership of the late Pierre Massion, which were published in the Journal of Respiratory and Critical Care Medicine in 2020.

The Vanderbilt Lung Institute, along with the Vanderbilt-Ingram Cancer Center, and the Lung Cancer Screening Program led by the Department of Radiology and Radiological Sciences, is now deploying the commercial software as part of its comprehensive care program to prevent, detect and treat lung cancer.

Lung cancer kills more people each year than any other cancer, and early detection is crucial to treatment and survival. Moreover, lung nodules are especially present in Tennessee due to a fungus called histoplasmosis. Most are not cancer, but it’s critical to detect the ones that are.

“That’s what this Optellum software will do. We are making a difference. Survival has improved. We think that has a lot to do with screening and early diagnosis.”
Otis Rickman, DO, Director of Interventional Pulmonology for the Vanderbilt Lung Institute.

Vanderbilt Lung Institute implements the Optellum Virtual Lung Nodule Clinic Post author:Rhiannon Lassiter Post published:January 4, 2022 Post category:Clinical / News and PR / Partners Vanderbilt University Hospital Medical Center (VUMC) is the first hospital in Tennessee to introduce Optellum’s ...

We’ve been in the news again this week as multiple outlets have covered our strategic collaboration with the Lung Cancer...
20/08/2021

We’ve been in the news again this week as multiple outlets have covered our strategic collaboration with the Lung Cancer Initiative at Johnson & Johnson.

A fast-growing lung health startup which aims to redefine early interception of lung cancer using AI decision support software has partnered with the Lung Cancer Initiative at Johnson & Johnson.

More good news for Optellum, grant funding and a partnership with 10 NHS hospitals for lung cancer prediction technology...
22/06/2021

More good news for Optellum, grant funding and a partnership with 10 NHS hospitals for lung cancer prediction technology.

Optellum wins NHS funding for its AI decision support to detect early-stage lung cancer this week. Optellum was one of thirty-eight companies to receive the funding, which was announced by the Secretary of State for Health and Social Care.

PRESS RELEASE: Optellum receives FDA clearance for the world's first clinical decision support software for early lung c...
07/04/2021

PRESS RELEASE: Optellum receives FDA clearance for the world's first clinical decision support software for early lung cancer diagnosis.

Virtual Nodule Clinic empowers clinicians to make optimal clinical decisions in early-stage lung cancer diagnosis and is now commercially available in the United States. Oxford, United Kingdom – March 23, 2021 – Optellum, a lung health company aiming to redefine early diagnosis and treatment of ...

In recent months, three new appointments have expanded the Optellum team to grow commercial adoption of the Optellum Vir...
11/01/2021

In recent months, three new appointments have expanded the Optellum team to grow commercial adoption of the Optellum Virtual Nodule Clinic software in the USA.

In recent months, three new appointments have expanded the Optellum team to grow commercial adoption of the Optellum Virtual Nodule Clinic software in the USA. Ryan Hennen (VP of US Sales) is a healthcare sales professional who brings twenty years’ experience consulting with large healthcare inte...

Address

Oxford Centre For Innovation
Oxford
OX11BY

Alerts

Be the first to know and let us send you an email when Optellum posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Early Interception of Lung Cancer

Optellum’s vision is to redefine cancer care, by enabling every clinician, in every hospital, to manage their patients in the optimal way.

We do that by providing end-end IT platform for personalized early diagnosis and therapy, based on the collective experience of thousands of doctors pooled by machine learning applied to vast patient datasets.

Our first suite of products targets management of patients at high risk of developing lung cancer – the world’s deadliest and commonest cancer – from early diagnosis through to treatment.

Optellum comprises a team of award-winning medical imaging software, AI, and clinical experts who met at Oxford’s world-renowned computer vision lab. Between us, we have track records of bringing innovation to market through over 10 start-up companies, resulting already in 5 trade-sales and one IPO. We are backed by an Advisory Board comprising world-leading clinicians and experts in deep learning ; and Oxford's most prominent investors.